H. Sudour

Learn More
Free doxorubicin (DXR) is not currently used to treat brain tumors because (i) the blood–brain barrier limits the drug deposition into the brain (ii) lethal toxic effects occur when combined with radiation therapy. Since encapsulation of DXR within liposomal carriers could overcome these drawbacks, the present study aimed at evaluating the radiosensitizing(More)
  • 1